Tag: multiple myeloma
#VisualAbstract GIMEMMA-MMY-3006: Bortezomib, Thalidomide, and Dexamethasone (VTD) Followed By Stem-Cell Transplantation Improves Long-Term Survival Outcomes in Newly Diagnosed Multiple Myeloma (MM)
Check out the original article from the Lancet Haematology here.
#VisualAbstract CASSIOPEIA Part 1: Bortezomib, Thalidomide, and Dexamethasone with Daratumumab (D-VTd) May Improve Quality of Life Post-Consolidation in Newly Diagnosed, Transplantation-Eligible Multiple Myeloma (MM) Patients
Check out the original article from the Lancet Haematology here.
Weekly selinexor, bortezomib, and dexamethasone demonstrates improved survival in treatment-refractory multiple myeloma
1. A once-per-week regime of selinexor, bortezomib and dexamethasone was associated with significantly improved progression-free survival versus current standard of ...
The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor
1. Approximately a quarter of multiple myeloma patients that had refractory disease despite treatment with a proteasome inhibitor, immunomodulatory agent, ...
Quick Take: Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
Multiple myeloma often develops from the precursor condition monoclonal gammopathy of undetermined significance (MGUS), which is detectable in peripheral blood. ...